Rob has worked in the life sciences arena for more than 25 years, beginning his career in academic and industry R&D before taking on roles in equity research, business development, strategic planning, and consulting. Rob’s prior experience in the areas of research tools/technologies, genomics, immunology and diagnostics is complemented by a breadth of work with clients ranging from start-ups to global pharmaceutical, diagnostic and research tool companies on projects spanning most therapeutic areas.
Prior to joining Huron, Rob was a Principal at The Frankel Group, a life sciences strategy consultancy. Before that, He was Director of Business Development and Strategic Planning at Transgenomic Inc., a genomics company with products/services supporting translational research, diagnostics and personalized medicine. Rob also worked in equity research at RBC Capital Markets.
Rob began his career as a scientist, initially as a Research Fellow at the Mayo Clinic, and subsequently at Wyeth Vaccines as a Sr. Research Scientist. His research pursuits have included regulation of gene expression, molecular & cellular immunology, and gene therapy of the immune system.
"Contract Manufacturing: Commodity or Competitive Edge?", Huron, 2016
"The Current State of Pharmaceutical Industry Research and Development: Increasing Translational Research to Improve R&D Productivitiy", The Frankel Group, December 2012
- Life Sciences
Precision Medicine / Diagnostics & Companion Diagnostics/ Research Tools & Technologies/ Life Sciences Strategy
- Life Sciences
PhD, Biological Chemistry, The University of Michigan
BS, Biochemistry, University of Minnesota